Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Pathophysiology of locus ceruleus neurons in a mouse model of Rett syndrome.

Taneja P, Ogier M, Brooks-Harris G, Schmid DA, Katz DM, Nelson SB.

J Neurosci. 2009 Sep 30;29(39):12187-95. doi: 10.1523/JNEUROSCI.3156-09.2009.

2.

Transgenic mice lacking serotonin neurons have severe apnea and high mortality during development.

Hodges MR, Wehner M, Aungst J, Smith JC, Richerson GB.

J Neurosci. 2009 Aug 19;29(33):10341-9. doi: 10.1523/JNEUROSCI.1963-09.2009.

3.

Breathing disorders in Rett syndrome: progressive neurochemical dysfunction in the respiratory network after birth.

Katz DM, Dutschmann M, Ramirez JM, Hilaire G.

Respir Physiol Neurobiol. 2009 Aug 31;168(1-2):101-8. doi: 10.1016/j.resp.2009.04.017. Epub 2009 Apr 24. Review.

4.

Mouse models of MeCP2 disorders share gene expression changes in the cerebellum and hypothalamus.

Ben-Shachar S, Chahrour M, Thaller C, Shaw CA, Zoghbi HY.

Hum Mol Genet. 2009 Jul 1;18(13):2431-42. doi: 10.1093/hmg/ddp181. Epub 2009 Apr 15.

5.

Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology.

Ballas N, Lioy DT, Grunseich C, Mandel G.

Nat Neurosci. 2009 Mar;12(3):311-7. doi: 10.1038/nn.2275. Epub 2009 Feb 22.

6.

Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety.

Thomas A, Burant A, Bui N, Graham D, Yuva-Paylor LA, Paylor R.

Psychopharmacology (Berl). 2009 Jun;204(2):361-73. doi: 10.1007/s00213-009-1466-y. Epub 2009 Feb 3.

7.

Evidence for both neuronal cell autonomous and nonautonomous effects of methyl-CpG-binding protein 2 in the cerebral cortex of female mice with Mecp2 mutation.

Belichenko NP, Belichenko PV, Mobley WC.

Neurobiol Dis. 2009 Apr;34(1):71-7. doi: 10.1016/j.nbd.2008.12.016. Epub 2009 Jan 8.

PMID:
19167498
8.

Deletion of Mecp2 in Sim1-expressing neurons reveals a critical role for MeCP2 in feeding behavior, aggression, and the response to stress.

Fyffe SL, Neul JL, Samaco RC, Chao HT, Ben-Shachar S, Moretti P, McGill BE, Goulding EH, Sullivan E, Tecott LH, Zoghbi HY.

Neuron. 2008 Sep 25;59(6):947-58. doi: 10.1016/j.neuron.2008.07.030.

9.

The history of dopamine and levodopa in the treatment of Parkinson's disease.

Fahn S.

Mov Disord. 2008;23 Suppl 3:S497-508. doi: 10.1002/mds.22028. Review.

PMID:
18781671
10.

The hyperactive syndrome: metanalysis of genetic alterations, pharmacological treatments and brain lesions which increase locomotor activity.

Viggiano D.

Behav Brain Res. 2008 Dec 1;194(1):1-14. doi: 10.1016/j.bbr.2008.06.033. Epub 2008 Jul 6. Review.

PMID:
18656502
11.

From gene to aggressive behavior: the role of brain serotonin.

Popova NK.

Neurosci Behav Physiol. 2008 Jun;38(5):471-5. doi: 10.1007/s11055-008-9004-7. Epub 2008 Jul 8. Review.

PMID:
18607754
12.

Evaluation of CSF neurotransmitters and folate in 25 patients with Rett disorder and effects of treatment.

Temudo T, Rios M, Prior C, Carrilho I, Santos M, Maciel P, Sequeiros J, Fonseca M, Monteiro J, Cabral P, Vieira JP, Ormazabal A, Artuch R.

Brain Dev. 2009 Jan;31(1):46-51. doi: 10.1016/j.braindev.2008.05.003. Epub 2008 Jun 24.

PMID:
18572337
13.

Movement disorders in Rett syndrome: an analysis of 60 patients with detected MECP2 mutation and correlation with mutation type.

Temudo T, Ramos E, Dias K, Barbot C, Vieira JP, Moreira A, Calado E, Carrilho I, Oliveira G, Levy A, Fonseca M, Cabral A, Cabral P, Monteiro JP, Borges L, Gomes R, Santos M, Sequeiros J, Maciel P.

Mov Disord. 2008 Jul 30;23(10):1384-90. doi: 10.1002/mds.22115.

PMID:
18512755
14.

MeCP2, a key contributor to neurological disease, activates and represses transcription.

Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, Zoghbi HY.

Science. 2008 May 30;320(5880):1224-9. doi: 10.1126/science.1153252.

15.

Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome.

Neul JL, Fang P, Barrish J, Lane J, Caeg EB, Smith EO, Zoghbi H, Percy A, Glaze DG.

Neurology. 2008 Apr 15;70(16):1313-21. doi: 10.1212/01.wnl.0000291011.54508.aa. Epub 2008 Mar 12.

16.

Investigating genotype-phenotype relationships in Rett syndrome using an international data set.

Bebbington A, Anderson A, Ravine D, Fyfe S, Pineda M, de Klerk N, Ben-Zeev B, Yatawara N, Percy A, Kaufmann WE, Leonard H.

Neurology. 2008 Mar 11;70(11):868-75. doi: 10.1212/01.wnl.0000304752.50773.ec.

PMID:
18332345
17.

A partial loss of function allele of methyl-CpG-binding protein 2 predicts a human neurodevelopmental syndrome.

Samaco RC, Fryer JD, Ren J, Fyffe S, Chao HT, Sun Y, Greer JJ, Zoghbi HY, Neul JL.

Hum Mol Genet. 2008 Jun 15;17(12):1718-27. doi: 10.1093/hmg/ddn062. Epub 2008 Mar 4.

18.

Clinical utility of monoamine neurotransmitter metabolite analysis in cerebrospinal fluid.

Hyland K.

Clin Chem. 2008 Apr;54(4):633-41. doi: 10.1373/clinchem.2007.099986. Epub 2008 Feb 29. Review.

19.

Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-range interaction with active genes.

Yasui DH, Peddada S, Bieda MC, Vallero RO, Hogart A, Nagarajan RP, Thatcher KN, Farnham PJ, Lasalle JM.

Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19416-21. Epub 2007 Nov 27.

20.

The story of Rett syndrome: from clinic to neurobiology.

Chahrour M, Zoghbi HY.

Neuron. 2007 Nov 8;56(3):422-37. Review.

Supplemental Content

Support Center